StockNews.AI
NRXS
StockNews.AI
106 days

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

1. NeurAxis will report Q1 2025 financial results on May 12, 2025. 2. Company focuses on neuromodulation therapies for chronic conditions. 3. The proprietary IB-Stim™ therapy is FDA cleared for IBS in adolescents. 4. Ongoing clinical trials target additional pediatric and adult conditions. 5. Forward-looking statements caution against reliance on predicted outcomes.

Earnings
-5.17%Current Return
VS
-0.98%S&P 500
$2.3205/05 09:07 AM EDTEvent Start
$2.205/06 03:46 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

Positive anticipation of Q1 results and ongoing product development may attract investors. Historical context shows such reports significantly influence stock prices, as seen with other biotech firms during pivotal announcements.

How important is it?

The upcoming earnings report is crucial for investor sentiment and market performance. Successful results can enhance confidence in NRXS and its therapies, directly influencing stock price.

Why Short Term?

Immediate investor sentiment will likely shift around the upcoming earnings announcement. Previous earnings announcements commonly produce stock movements shortly thereafter.

Related Companies

IBTXMDVLNVCR
CARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its first quarter 2025, for the period ended March 31, 2025, on Monday, May 12, 2025, before market open. The Company has scheduled a conference call for the same day, Monday, May 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Monday, May 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/hn59d9cm. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com. Call-in Information: Interested parties can also access the live conference call by initially registering at the following link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details. Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/hn59d9cm. About NeurAxis, Inc.NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contacts: CompanyNeurAxis, Inc.info@neuraxis.com Investor RelationsBen ShamsianLytham Partners646-829-9701shamsian@lythampartners.com

Related News